Pharmacology of serotonin as related to anesthesia

Journal of Clinical Anesthesia

Volumn 8, Issue 5, 1996, Pages 402-425

  Gyermek, Laszlo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

5 HT receptor agonists; 5 HT receptor antagonists; 5 HT uptake inhibitors; Antiemetics; dolasetron; granisetron; ketanserin; nausea and vomiting; ondansetron; psychopharmacology; serotonin; sumatriptan; tropisetron

Indexed keywords

DOLASETRON MESILATE; GRANISETRON; GUANINE NUCLEOTIDE BINDING PROTEIN; KETANSERIN; ONDANSETRON; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 1 AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TROPISETRON;

ANESTHESIA; ANXIETY NEUROSIS; CARCINOID SYNDROME; DEMENTIA; DEPRESSION; DRUG MECHANISM; GASTROINTESTINAL MOTILITY; HUMAN; MENTAL DISEASE; MIGRAINE; NAUSEA; NONHUMAN; PERSONALITY DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; VASCULAR DISEASE; VOMITING;

EID: 0030222156     PISSN: 09528180     EISSN: None     Source Type: Journal    
DOI: 10.1016/0952-8180(96)00093-1     Document Type: Article

References (232)

1. 1. Erspamer V: Pharmacology of indolealkylamines. Pharmacol Rev 1954;6:425-87.
2. 2. Page IH: Serotonin (5-hydroxytryptamine). Physiol Rev 1954;34: 553-88.
3. 3. Erspamer V (ed): 5-Hydroxytryptamine and related indolealkylamines. Handbook of Experimental Pharmacology, vol. 19. Berlin: Springer, 1966.
4. 4. Garattini S, Valzelli L: Serotonin. Amsterdam: Elsevier, 1965.
5. 5. Page IH: Serotonin. Chicago: Year Book Medical Publishers, 1968.
6. 6. Wooley DW, Shaw E: Evidence for the participation of serotonin in mental process. Ann NY Acad Sci 1957;66:649-67.
7. 7. Gaddum JH: Serotonin LSD interactions. Ann NY Acad Sci 1957; 66:646-8.
8. 8. Aghajanian GK, Graham AW, Sheard MH: Serotonin containing neurons in the brain: depression of firing by monoamine oxidase inhibitors. Science 1970;169:1100-2.
9. 3H) spiroperidol. Mol Pharmacol 1979;16:687-99.
10. 10. Reiter RJ: Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endo Rev 1991;12:151-80.
11. 11. Kopin IJ, Pare CMB, Axelrod J, Weissbach H: The fate of melatonin in animals. J Biol Chem 1961;236:3072-5.
12. 12. Krause DN Dubocovich ML: Melatonin receptors. Ann Rev Pharmacol Toxicol 1991;31:549.
13. 13. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W: Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958;80:2587.
14. 14. Reiter RJ, Tan DX, Poeggeler B, Menendez-Pelaez A, Chen LD, Saarela S: Melatonin as a free radical scavenger: implications for aging and age-related diseases. In: Pierpaoli W, Regelson W, Fabris N (eds): The Aging Clock. Ann NY Acad Sci 1993;719:1-11.
15. 15. Franschini F, Stankov B: New molecules active at the melatonin receptor level. In: Fraschini F, Reiter RJ, Stankov B (eds): The Pineal Gland and its Hormones. New York: Plenum Press, 1995: 131-8.
16. 16. Pierpaoli W, Regelson W, Fabris N (eds): The Aging Clock. Ann NY York Acad Sci, 1993;719.
17. 17. Delagrange P, Renard R, Caignard DH, and Guardiola-Lemaitre B: Development of melatonin analogues. In: Franschini F, Reiter RJ, Stankov B (eds): The Pineal gland and its Hormones. NY: Plenum Press, 1995:139-54.
18. 18. Cardinali DP, Glombck DA, Rosentein RE, Kanterewicz BA, and Fiszman M: Chronobiological activity of melatonin: Mediation by gabaergic mechanisms. In: Fraschini F, Reiter RJ, Stankov B (eds) : The Pineal Gland and its Hormones. NY: Plenum Press, 1995:119-38.
19. 19. Gluchowski C, Branchek TA, Weinshank RL, et al: Molecular cell biology of G protein-coupled CNS receptors, In: Bristol JA (ed): Annual Review of Medical Chemistry, vol. 28. San Diego: Academic Press, 1993:29-38.
20. 20. Roth BL, Craigo SC, Choudhary MS, et al: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268: 1403-10.
21. 21. Zifa E, Fillion G: 5-Hydroxytryptamine receptors. Pharmacol Rev 1992;44:402-58.
22. 22. Humphrey PP, Hartig P, Hoyer D: A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 1993;14:233-6.
23. 23. Elsel' JL, Bertrand S, Galzi JL, Devillers-Thi'ry A, Changeux JP, Bertrand D: Chimaeric nicotinic serotoninergic receptor combines distinct ligand binding and channel specificities. Nature 1993;366:479-83.
24. 24. Bockaert J: Serotonin receptors: from genes to pathology. In: Langer SZ, Brunello N, Racagni G, Mendleweiz (eds): Critical Issues of the Treatment of Affective Disorders. Basel: Karger, 1994:1-8.
25. 25. Gottfries CG: Serotonergic mechanisms in age-related cognitive impairment and dementias. In: Racagni G, Brunello N, Langer SZ (eds): Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. International Academic Biomedical Drug Research, Vol. 7. Basel: Karger, 1994:82-8.
26. 26. Fuller RW: Pharmacology of central serotonin neurons. Ann Rev Pharmacol Toxicol 1980;20:111-27.
27. 27. Briley M: Imipramine binding: its relationship with serotonin uptake and depression. In: Green AR (ed): Neuropharmacology of Serotonin. Oxford: Oxford University Press, 1985:50-78.
28. 28. Heym J, Koe BK: Pharmacology of sertraline: a review. J Clin Psychiatry 1988;49(Suppl):40-5.
29. 29. De Montigny C, Blier P: Electrophysiological aspects of serotonin neuropharmacology: Implications for antidepressant treatments. In: Green AR (ed): Neuropharmacology of Serotonin; Oxford: Oxford Med Publishers, 1985.
30. 30. Siever LJ, Kahn RS, Lawlor BA, Trestman RL, Lawrence TL, and Coccaro EF: Critical issues in defining the role of serotonin in psychiatric disorders. Pharmacol Rev 1991;43:509-25.
31. 31. Göthert M: Presynaptic serotonin receptors in the central nervous system. Ann NY Acad Sci 1990;604:102-12.
32. 32. Sulser F, Gillespie Dd, Mishra R, Manier DH: Desensitization by antidepressants of central norepinephrine receptor systems coupled to adenylate cyclase. Ann NY Acad Sci 1984;430:91-101.
33. 33. Kahn RS, van Praag HM, Wetzler S, Asnis GM, Barr G: Serotonin and anxiety revisited. Biol Psychiatry 1988;23:189-208.
34. 34. Lapin IP, Oxenkrug GF: Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969;1(586):132-6.
35. 35. Ansseau M: The paradox of neurochemical and clinical properties of serotonergic antidepressants. In: Langer SZ, Brunello N, Racagni G, Medlewicz J (eds): Critical Issues in the Treatment of Affective Disorders. International Academic Biomedical Drug Research, vol. 9. Basel: Karger, 1994:127-35.
36. 36. Aprison MH, Hintgen JN, Nagayama H: Testing a new theory of depression with an animal model: neurochemical-behavioral evidence for postsynaptic receptor involvement. In: Langer SZ, Takahashi R, Segawa T, Briley M (eds): New Vistas in Depression. New York: Pergamon Press, 1982:171-8.
37. 37. Willner P: Depression a Psychobiological Synthesis. New York: Wiley, 1985.
38. 38. Himwich HE: Indoleamines and the depressions. Part I. Indoleamine metabolism in depressed patients free of psychotropic drugs. In: Himwich HE (ed): Biochemistry, Schizophrenias and Affective Illness. Baltimore: Williams and Wilkins, 1979:230-82.
39. 39. Gyermek L: Drugs which antagonize 5-hydroxytryptamine and related indolealkylamiens. In: Erspamer V (ed): Handbook of Experimental Pharmacology, vol. 19. Berlin: Springer, 1966:471-528.
40. 40. Murphy DL, Lesch KP, Aulakh CS, Pigott TA: Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev l991;43:527-52.
41. 41. Meltzer HY, Lowy MT: The serotonin hypothesis of depression. In: Meltzer HY (ed): Psycopharmacology: The third Generation of Progress. New York: Raven Press, 1987:513-26.
42. 1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987;1:470-80.
43. 1A agonist. In: Saxena PR, Wallis DI, Wouters W, Bevan P (eds): Cardiovascular Pharmacology of 5-HT: Prospective Therapeutic Applications, vol. 35. Dordrecht: Kluwer, 1990:355-9.
44. 44. Sanders KH, Beller KD, Bischler P, Kolassa N: Interaction of urapidil with brain serotonin-1A receptors increases the blood pressure reduction due to peripheral alpha-adrenoceptor inhibition. J Hypertension 1988;6(Suppl):S65-8.
45. 45. Lesch KP, Aulakh CS, Murphy DL: Brain serotonin subsystem complexity receptor heterogeneity: therapeutic potential of selective serotonin agonists and antagonists. Psychopharmacol Ser 1993;10:52-69.
46. 46. Treatment of migraine attacks with Sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Eng J Med 1991;325:316-21.
47. 47. Hannington-Kiff JG: Sumatripian relieves and prevents perioperative migraine attacks. Anaesthesia 1990;48:144-6.
48. 2 antagonists, 1.2-and 6-substituted 1-phenyl-3-(4-piperidinyl)-1H-indoles. J Med Chem 1992;35: 4813-22.
49. 3 receptors in vitro and in vivo. Eur J Pharmacol 1993;237:299-309.
50. 4 receptor. Int Clin Psychopharmacol 1993;8(2):11-18.
51. 51. Hindle AT: Recent developments in the physiology and pharmacology of 5-hydroxytryptamine. Br J Anaesth 1994;73:395-407.
52. 52. McHugh S, Lico S, Diament NE: Cisapride versus rnetochlopramide. An Acute study in diabetic gastroparesis. Digest Dis Sci 1992;37:997-1001.
53. 4 receptors. Trends Pharmacol Sci 1995;16:391-8.
54. 54. Arvidsson LE, Hacksell U, Glennon RA: Recent advances in central 5-hydroxytryptamine receptor agonists and antagonists. Prog Drug Res 1986;30:365-471.
55. 3 receptor antagonists. In: Jones B, King FD, and Sanger G (eds): 5-Hydroxytryptamine receptor antagonists. Boca Raton, FL: CRC Press, 1994: 2-44.
56. 56. Glennon RA, Dukat M: 5-HT receptor Ligands-update 1992. In: Current Drugs: Serotonin, Current Drugs Ltd ISSN 0962-2594
57. 2 serotonergic receptors. J Pharmacol Exp Ther 1981;218:217-30.
58. 58. Marwood JF, Stokes GS: Serotonin (5HT) and its antagonists: involvement in the cardiovascular system. Clin Exp Pharmacol Physiol 1984;11:439-56.
59. 59. Anderson A, Morgan T, Dumpys R: The effect of ketanserin in essential hypertension. Clin Exp Pharmacol Physiol 1983;10:331-3.
60. 2 serotonin receptor binding. J Med Chem 1995;38:1196-202.
61. 61. Hodsman NBA, Colvin JR, Kenny GN: Effect of ketanserin on sodium nitroprusside requirements, arterial pressure control and heart rate following coronary artery bypass surgery. Br J Anaesth 1989;62:527-31.
62. 62. Murrary WB, Daniel CH: Ketanserin and the cardiovascular response to intubation: a preliminary report. Eur J Anaesthesiol 1987;4:401-9.
63. 3 receptor antagonist. Anesth Analg 1991;72:751-5.
64. 64. Bodner M, White PF: Antiemetic efficacy of ondansetron after outpatient laparoscopy. Anesth Analg 1991;73:250-4.
65. 65. Harmer M (ed): Ondansetron - a new concept in antiemetic therapy for postoperative nausea and vomiting (PONV). Anaesthesia 1994;49(Suppl):2-37.
66. 66. Bunce KT, Tyers MB: The role of 5-HT in postoperative nausea and vomiting. Br J Anaesth 1992;69(Suppl):60S-68S.
67. 3 receptors: pharmacologic and therapeutic aspects. J Clin Pharmarol 1995;35:845-55.
68. 68. Pintens H: Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary. Cancer Treatment Rev 1990;17:307-10.
69. 3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1987;1(8543):1198.
70. 3 receptor antagonist. Lancet 1987;1(8548):1461-3.
71. 71. Jones AL, Hill AS, Soukop M, et al: Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991;338(8765): 483-7.
72. 3 receptor antagonists: review of preclinical and clinical results with ICS 205-930. Cancer Treatment Rev 1990;17:302-5.
73. 73. Hainsworth J, Harvey W, Pendergrass K, et al: A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991;9:721-8.
74. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991;42:551-68.
75. 75. Andrews PL, Rapeport WG, Sanger GJ: Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988;9:334-41.
76. 76. Lucot JB, Crampton GH: 8-OH-DPAT suppresses vomiting in the cat elicited by motion, cisplatin or xylazine. Pharmacol Biochem Behav 1989;33:627-31.
77. 77. Larijani GE, Gratz I, Afshar M, Minassian S: Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo. Anesth Analg 1991; 73:264-9.
78. 78. Alon E, Himmelseher S: Ondansetron in the treatment of postoperative vomiting: a randomized double-blind comparison with droperidol and metoclopramide. Anesth Analg 1992;75: 561-5.
79. 79. Diemunsch P, Wilson J, Chitour K, et al: A double-blind, parallel group, placebo-controlled dose ranging study of IV granisetron in the prevention of postoperative nausea and vomiting [Abstract]. Anesthesiology 1994;81:A1280.
80. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 1992;219:9-13.
81. 3 antagonist, in cancer patients treated with cisplatin. European Dolasetron study group. Am J Clin Oncol 1994;17:97-102.
82. 82. Jacobsen MB: Ondansetron in carcinoid syndrome [Letter]. Lancet 1992;340(8812):185.
83. 83. Zomers PJ, Langenberg CJ, de Bruijn KM: Tropisetron for postoperative nausea and vomiting in patients after gynaecological surgery. Br J Anaesth 1993;71:677-80.
84. 84. Kaufmann MA, Rosow C, Schnieper P, Schneider M: Prophylactic antiemetic therapy with patient-controlled analgesia: a double-blind, placebo-controlled comparison of droperidol, metoclopramide, and tropisetron. Anesth Analg 1994;78:988-94.
85. 3 receptor antagonist. Drug Dev Res 1992;25:17-28.
86. 86. Cowen PJ: Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatry 1991;12(Suppl):7-14.
87. 3 receptors. Pharmacol Toxicol 1992;71:401-15.
88. 88. Gaginella TS, Galligan JJ (eds): Serotonin and Gastrointestinal Function. Boca Raton, FL: CRC Press, 1995.
89. 4 receptor: a place in the sun. Trends Pharmacol Sci 1992;12:141-5.
90. 90. Gale JD, Bunce K: Pharmacological characterization of 5-hydroxytryptamine receptors in the gastrointestinal tract. In: Gaginella TS, Galligan JJ (eds): Serotonin and Gastrointestinal Function. Boca Raton, FL: CRC Press, 1995:33-52.
91. 91. File SE, Andrews N, Fernandes C, Gonzalez LE: The role of 5-HT ligands in treating benzodiazepine and alcohol withdrawal. In: Langer SZ, Brunello N, Racagni G, Mendlewicz J (eds): Critical Issues in the Treatment of Affective Disorders. International Academic Biomedical Drug Research, vol. 9. Basel: Karger, 1994:90-7.
92. 4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285. Naunyn Schmiedebergs Arch Pharmacol 1992;345:264-9.
93. 4 receptors in the isolated guinea pig ileum. Eur J Pharmacol 1991;200:373-4.
94. 94. Vanhoutte PM (ed): Serotonin and the Cardiovascular System. NY: Raven Press, 1985.
95. 95. Mir AK, Fozard JR: 5-Hydroxytryptamine in central cardiovascular regulation. In: Saxena PR, Wallis DI, Wuoters W, Bevan P (eds): Cardiovascular Pharmacology of 5-Hydroxytryptamine, Prospective Therapeutic Applications. Dordrecht: Kluwer, 1990:101-16.
96. 96. Chalmers JP, Wing LM: Central serotonin and cardiovascular control. Clin Exp Pharmacol Physiol 1975;Suppl 2:195-200.
97. 97. Wolf WA, Kuhn DM, Lovenberg W: Serotonin and central regulation of arterial blood pressure. In: Vanhouette PM (ed): Serotonin and the Cardiovascular system. NY: Raven Press, 1985.
98. 98. Palacios JM, Waeber C, Hoyer D, Mengod G: Distribution of serotonin receptors. Ann NY Acad Sci 1990;600:36-52.
99. 99. Fozard JR, Ali AT: Receptors for 5-hydroxytryptamine on the sympathetic nerves of the rabbit heart. Naunyn Schmiedebergs Arch Pharmacol 1978;301:223-35.
100. 100. Olssen S, Edwards IR: Tachycardia during cisapride treatment. BMJ 1992:305:748-9.
101. 3 receptor subtypes. Brain Res 1991;561:61-8.
102. 102. Cocks TM, Angus JA: Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 1983; 305:627-30.
103. 103. McGrath MA: 5-hydroxytryptamine and neurotransmitter release in canine blood vessels, inhibition by low and augmentation by concentrations. Circ Res 1977;41:428-35.
104. 104. Althaus JS, Beckman JJ, Miller ED Jr: Central seroionin depletion: effect on blood pressure during anesthesia. Anesth Analg 1985;64:1163-70.
105. 105. Hollenberg NK: Serotonin and vascular responses. Ann Rev Pharmacol Toxicol 1988;28:41-59.
106. 106. Parsons AA, Whalley EJ, Feniuk W, Connor HE, Humphrey PP: 5-HT like receptors mediate 5-Hydroxytryptamine induced contractions of human isolated basilar artery. Br J Pharmacol 1989; 96:434-49.
107. 107. Rodegra H, Roeder G, Schmermund HJ, Soehring UK: The effect of hydroxytryptamine on the isolated umbilical artery. Naunyn-Schmiedebergs Arch Exp Path Pharmak 1957;232:285-6.
108. 108. Feldberg W, Smith AN: Release of histamine by tryptamine and 5-hydroxytryptamine. Br J Pharmacol 1953;8:406-11.
109. 109. Adam-Vizi VA, Vizi ES: Direct evidence of acetylcholine releasing effect of serotonin in the Auerbach plexus. J Neural Transm 1978;42:127-38.
110. 110. Meehan AG, Story DF, Medgett IC: Influence of the endothelium on the amplification by serotonin of vasoconstrictor responses to noradrenaline and sympathetic nerve stimulation in rabbit isolated ear artery. Eur J Pharmacol 1987;141:339-46.
111. 111. Fukuda S, Su C, Lee TJ: Potentiation of pressor responses to serotonin by ketamine in isolated perfused rat mesentery. J Cardiovasc Pharmacol 1986;8:765-70.
112. 112. Marsh HM, Martin JK Jr, Kvols LK, et al: Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. Anesthesiology 1987;66:89-91.
113. 113. Haeusler G, Finch L: Vascular reactivity to 5-hydroxytryptamine and hypertension in the rat. Naunyn-Schmiedebergs Arch Pharmacol 1972;272:101-16.
114. 114. Ludmer PL, Selwyn AP, Shook TL, et al: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
115. 2-serotonergic blockade. J Pharmacol Exp Ther 1986; 237:548-52.
116. 116. Fozard J: A critique of migraine therapy. In: Rose FC (ed): The Management of Headache. NY: Raven Press, 1988:99-114.
117. 117. Moskowitz MA, Cutrer FM: Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med 1993;44:145-54.
118. 118. Roberts WC, Sjoerdsma A: The cardiac disease associated with the carcinoid syndrome (carcinoid heart disease). Am J Med 1964;36:5-34.
119. 119. Brazenor RM, Angus JA: Actions of serotonin antagonists on dog coronary artery. Eur J Pharmacol 1982;81:569-76.
120. 120. Ashton JH, Benedict CR, Fitzgerald C, et al: Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986;73:572-8.
121. 121. Comroe J, Vanlingen B, Stroud R, Roncoroni A: Reflex and direct cardiopulmonary effects of 5-OH-tryptamine (serotonin). Am J Physiol 1953;173:379-86.
122. 122. James TN: A cardiogenic hypertensive chemoreflex. Anesth Analg 1989;69:633-46.
123. 2-serotonergic antagonist ketanserin. In: Vanhouette PM (ed): Serotonin and the Cardiovascular System. NY: Raven Press, 1985:88-93.
124. 3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache. Headache 1991;31:296-7.
125. 125. Spatz M: Serotonin and cardiac disease. In: Essmann WB (ed): Serotonin in Health and Disease. NY: Spectrum Publishers, 1978: 389-401.
126. 126. Ahlman H, Wangberg B, Jansson S, et al: Management of disseminated midgut carcinoid tumors. Digestion 1991;49:78-96.
127. 127. Platt AJ, Heddle RM, Rake MO, Smedley H: Ondansetron in carcinoid syndrome [Letter]. Lancet 1992;339(8806):1416.
128. 128. Quinlivan JK, Roberts WA: Intraoperative octreotide for refractory carcinoid-induced bronchospasm. Anesth Analg 1994;78: 400-2.
129. 129. Murphy DL: Peripheral indices of central serotonin function in humans. Ann NY Acad Sci 1990;600:282-95.
130. 130. Costa JL, Silber SA, Murphy DL: Effects of reserpine and imipramine on vesicular serotonin uptake and storage in intact human platelets. Life Sci 1977;21:181-8.
131. 131. Verstraete M: Platelet activation in patients with atherosclerosis of the arteries of the limbs. In: Vanouette PM (ed): Serotonin and the Cardiovascular System. NY: Raven Press, 1985:171-8.
132. 132. Mehendale HM: Pulmonary disposition and effects of drugs on pulmonary removal of endogenous substances. Fed Proc 1984; 43:2586-91.
133. 133. Alabaster VA, Bakhle YS: Removal of 5-hydroxytryptamine in the pulmonary circulation of rat isolated lungs. Br J Pharmacol 1970; 40:468-82.
134. 134. Skillen R, Thiences C, Cangelosi J, Stram L: Lung 5-hydroxytryptamine and ozone-induced pulmonary edema in rats. Proc Soc Exp Biol Med 1961;107:178-80.
135. 135. Cook DR, Howell RE, Gillis CN: Xanthine oxidase-induced lung injury inhibits removal of 5-hydroxytryptamine from the pulmonary circulation. Anesth Analg 1982;61:666-70.
136. 136. Cook DR, Braudom BW: Euflurane, halothane, and isoflurane inhibit removal of 5-hydroxytryptamine from the pulmonary circulation. Anesth Analg 1982;61:671-5.
137. 137. Herxheimer H: The bronchial reaction of guinea pigs to 5-hydroxytryptamine. J Physiol 1953;120:65-6.
138. 138. Reiche R, Frey HH: Antagonism of the 5-hydroxytryptamine-induced bronchoconstriction in the cat. Arch Int Pharmacodyn Ther 1983;263:139-45.
139. 139. Steinberg H, Fisher A: Serotenin in the lung. In: Essmann WB (ed): Serotonin in Health and Disease. NY: Spectrum Publishers. 1979:69-109.
140. 140. Stone HH, Nemir P Jr: Study of the role of 5-hydroxytryptamine (serotonin) and histamine in the pathogenesis of pulmonary embolism in man. Ann Surg 1960;152:890-900.
141. 141. Sibbald W, Peters S, Lindsay RM: Serotonin and pulmonary hypertension in human septic ARDS. Crit Care Med 1980; 8:490-4.
142. 142. Hechtman HB: Serotonin and acute respiratory failure. In: Vanhouette PM (ed): Serotonin and the Cardiovascular System. NY: Raven Press, 1985:213-23.
143. 143. Gaddum JH, Picarelli ZP: Two kinds of tryptamine receptor. Br J Pharmacol Chemother 1957;12:323-8.
144. 144. Buchheit KH, Engel G, Mutschier E, Richardson B: Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn-Schmiedebergs Arch Pharmacol 1985;329:36-41.
145. 145. Gaginella TS: Serotonin in the intestinal tract: a synopsis. In: Gaginella TS, Galligan JJ (eds): Serotonin and Gastrointestinal Function. pp 1-9, Boca Raton, EL: CRC Press, 1995:1-9.
146. 146. Gyermek L: Action of 5-hydroxytryptamine on the urinary bladder of the dog. Arch Int Pharmacodyn 1961;137:137-44.
147. 2-type. J Anton Pharmacol 1985;5:101-7.
148. 148. Trendelenburg U: Pharmacology of autonomic ganglia. Ann Rev Pharmacol 1961;1:219-38.
149. 149. Gyermek L, Bindler E: Blockade of the ganglionic stimulant action of 5-hydroxytryptamine. J Pharmacol Exp Ther 1962;135: 344-68.
150. 150. Haefely W: The effects of 5-hydroxytryptamine and some related compounds on the cat superior cervical ganglion in situ. Naunyn-Schmiedebergs Arch Pharmacol 1974;281:145-65.
151. 151. de Groat WC, Booth AM: Inhibition and facilitation in parasympathetic ganglia of the urinary bladder. Fed Proc 1980;39:2990-6.
152. 152. Fozard JR: Neuronal 5-HT receptors in the periphery. Neuropharmacology 1984;23:1473-86.
153. 3 receptors of the rat, mouse and guinea-pig superior cervical ganglion may be different. Br J Pharmacol 1991;102:615-20.
154. 154. Nishimura T, Akasu T: 5-Hydroxytryptamine produces presynaptic facilitation of cholinergic transmission in rabbit parasympathetic ganglia. J Auton Nerv Syst 1989;26:251-60.
155. 155. McQueen DS, and Mir AK: 5-Hydroxytryptamine and cardiopulmonary and carotid body reflex mechanisms. In: Fozard JR (ed): The peripheral actions of 5-hydroxytryptamine. Oxford: Oxford University Press, 1989:301-26.
156. 156. Moret C: Pharmacology of the serotonin autoreceptor. In: Green AR (ed): Neuropharmacology of Serotonin. Oxford: Oxford Med Publishers, 1985:21-49.
157. 157. Galligan JJ: Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons. In: Gaginella TS, Galligan JJ (eds): Serotonin and Gastrointestinal function. Boca Raton, FL: CRC Press, 1995:109-26.
158. 3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993;7:175-80.
159. 4 receptor dual antagonist on colonic function in vivo. J Pharmacol Exp Ther 1993;266:74-80.
160. 3 receptor antagonists. 2. 4-Hydroxy-3-quinolinecarboxylic acid derivatives. J Med Chem 1993;36:617-26.
161. 3 receptors. Pharmacol Toxicol 1994;71:401-15.
162. 162. Bhattacharyya BJ, Sokoll MD, Long JP: Effect of (±)-DOI on neuromuscular transmission: a microelectrode study. Eur J Pharmacol 1991;195:171-4.
163. 163. Lien CA, Gadalla F, Kudlak TT, Embree PB, Sharp GJ, Savarese JJ: The effect of ondansetron on atracurium-induced neuromuscular blockade. J Clin Anesth 1993;5:399-403.
164. 164. Brodie BB, Shore PA: A concept for a role of serotonin and norepinephrine as chemical mediators in the brain. Ann NY Acad Sci 1957;66:631-42.
165. 165. Gyermek L: The pharmacology of imipramine and related antidepressants. Int Rev Neurobiol 1966;9:95-143.
166. 166. Gyermek L, Sumi T: Potentiating actions of indole alkylamines and lysergic acid diethylamide on reflexes elicited by 5-hydroxytryptamine. Proc Soc Biol Med 1963;114:436-9.
167. 167. Carlsson A, Corrodi H, Fuxe K, Hökfelt T: Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl alpha-ethyl-meta-tyramine. Eur J Pharmacol 1969;5:357-66.
168. 168. Fuxe K, Hökfelt T, Ungerstedt U: Morphological and functional aspects of central monoamine neurons. In: International Review of Neurobiology, vol. 13. NY: Academic Press, 1970:93-126.
169. 169. Green AR (ed): Neuropharmacology of Serotonin. Oxford: Oxford Med Publishers, 1985.
170. 170. Fornal CA, Jacobs LJ: Physiological and behavioral correlates of serotonergic single-unit activity. In: Osborne NN, Hammon M (eds): Neuronal Serotonin. London: John Wiley and Sons Ltd, 1988:305-45.
171. 171. Whitaker-Azmitia PM, Peroutka SJ: The Neuropharmacology of Serotonin, vol. 600. Ann NY Acad Sci 1988.
172. 172. Grahame-Smith DG: Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxydase inhibitor and L-tryptophan. J Neurochem 1971;18:1053-66.
173. 173. Jacobs BL, Fornal CA: Activity of brain serotonergic neurons in the behaving animal. Pharmacol Rev 1991;43:563-78.
174. 174. Meltzer HY, Nash JF: Effects of and psychotic drugs on serotonin receptors. Pharmacol Rev 1991;43:587-604.
175. 2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem 1995;38:1119-31.
176. 3 Antagonist and Disorders of Cognition. In: Racagni G, Brunello N, and Langer SZ (eds): Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. International Academic Biomedical Drug Research, vol. 7. Basel: Karger, 1994:89-93.
177. 3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature 1988;267:741-43.
178. 4 receptor subtype inhibits K+ current in colliculi neurons via activation of a cyclic AMP-dependent protein kinase. Br J Pharmacol 1992;105: 973-9.
179. 179. Peroutka SJ: Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT1D and 5-HT3 receptor agents. Pharmacol Rev 1991;43:579-86.
180. 3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 1989;10:127-9.
181. 2-adrenergic heteroreceptors on serotonin terminals in the mechanism of action of antidepressant drugs. In: Langer SZ, Brunello N, Racagni G, Mendlewicz J (eds): Critical Issues in the Treatment of Affective Disorders. International Academic Biomedical Drug Research, vol. 9. Basel: Karger, 1994:98-109.
182. 182. Elsworth JD, Taylor JR, Jatlow P, Roth RH: Serotonin involvement in cocaine sensitization: clues from studies with cocaine analogs. Drug Dev Res 1993;30:189-200.
183. 183. Wallis CJ, Rezazadeh SM, Lal H: Role of serotonin in ethanol abuse. Drug Dev Res 1993;30:178-88.
184. 184. McBride WJ, Murphy JM, Yoshimoto K, Lumeng L, Li TK: Serotonin mechanisms in alcohol drinking behavior. Drug Dev Res 1993;170-7.
185. 185. Fadda F, Mosca E, Colombo G, Gessa GL: Alcohol preferring rats: genetic sensitivity to alcohol-induced stimulation of dopamine metabolism. Physiol Behav 1990;47:727-9.
186. 3 receptors attenuates the effects of ethanol on extracellular dopamine. Eur J Pharmacol 1990;187:287-9.
187. 187. Tollefson GD: Anxiety and alcoholism: a serotonin link. Br J Psychiatry 1991;12(Suppl):34-9.
188. 188. Jouvet MM, Denover M, Kitahama K, Sallanon M: Slow wave sleep and indoleamines: A hypothalamic target. In: Wauquier A, Dugovic C, and Radulovacki M (eds): Slow Wave Sleep: Physiological, Pathophysiological and Functional aspects. New York: Raven Press, 1989:98-108.
189. 189. Wauquier A, Dugovic C: Serotonin and sleep-wakefulness. Ann NY Acad Sci 1990;600:447-58.
190. 190. Griffiths R, Norman RI: Effects of anesthetics on uptake, synthesis and release of transmitters. Br J Anaesth 1993;71:96-107.
191. 191. Bloom FE, Hoffer BJ, Nelson C, Sheu Y, Siggins GR: The physiology and pharmacology of serotonin mediated synapses. In: Barchas J and Usdin E (eds): Serotonin and Behavior, New York: Academic Press, 1973:249-61.
192. 192. Slater IH, Davis KH, Leary DE, Bovd ES: The action of serotonin and lysergic acid diethylamide on spinal reflexes. J Pharmacol Exp Ther 1955;113:48-9.
193. 193. Marley E, Vane JR: Tryptamine and spinal cord reflexes in cats. Br J Pharmacol Chamother 1967;31:446-65.
194. 194. Maj J, Palider W, Baran L: The effects of serotonergic and antiserotonergic drugs on the flexor reflex of spinal rat: a proposed model to evaluate the action on the central serotonin receptor. J Neural Transm 1976;38:131-47.
195. 195. Myers RD, Waller MB: Thermoregulation and serotonin. In: Essman WB (ed); Serotonin in Health and Disease, Vol II: Physiological Regulation and Pharmacological Action. New York: Spectrum Publishers 1978:1-67.
196. 196. Gudelsky GA, Koenig JI, Meltzer HY: Thermoregulaton responses to setotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology 1986;25:1307-13.
197. 197. Cowen PJ, Anderson IM, Gartside SE: Endocrinological responses to 5-HT. Ann NY Acad Sci 1990;600:250-7.
198. 198. Tuomisto J, Mannisto P: Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 1985;37:249-332.
199. 199. Koenig JI, GudeLsky GA, Meltzer HY: Stimulation of corticosterone and β-endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur J Pharmacol 1987;137:1-8.
200. 200. Van De Kar LD: Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Ann Rev Pharmacol Toxicol 1991;32:289-320.
201. 201. Blundell JE: Serotonin and appetite. Neuropharmacology 1984;23: 1537-51.
202. 202. Nicolaidis S: Serotoninergic System, Feeding and Body Weight Regulation. London: Academic Press, 1986.
203. 203. Curzon G: Serotonin and appetite. Ann NY Acad Sci 1990;600: 521-30.
204. 204. Le Bars D: Serotonin and pain. In: Osborne NN, Hamon M (eds): Neuronal Serotonin. Chishester, England: John Wiley and Sons, 1988:171-229.
205. 205. Armstrong D, Dry RM, Keele CA, Markham JW: Observations on chemical excitants of cutaneous pain in man. J Physiol 1953;120: 326-51.
206. 206. Sigg EB, Caprio G, Schneider JA: Synergism of amines and antagonism of reserpine to morphine and analgesia. Proc Soc Exp Biol Med 1958;97:97-100.
207. 3H-5-hydroxytryptamine from brain during acupuncture and morphine analgesia. Sci Sinica 1977;20:223-124.
208. 208. Guilbaud G, Besson JM, Oliveras JL, Liebeskind JC: Suppression by LSD of the inhibitory effect exerted by dorsal raphe stimulation on certain spinal cord interneurons in the cat. Brain Res 1973;61:417-22.
209. 209. Yaksh TL, Du Chateau JC, Rudy RA: Antagonism by methysergide and cinanserin of the antinociceptive action of morphine administered in the periaqueductal gray. Brain Res 1976;104: 367-72.
210. 210. Yaksh TL, Wilson PR: Spinal serotonin terminal system mediates antinociception. J Pharmacol Exp Ther 1979;208:446-53.
211. 211. Fennessy MR, Lee JR: Modification of morphine analgesia by drugs affecting adrenergic and tryptaminergic mechanisms. J Pharm Pharmacol 1970;22:930-5.
212. 212. Noel MA, Mays KS, Byrne WL: Oral tryptophan as a potential adjunctive therapy in chronic pain patients. In: Way L (ed): Endogenous and Exogenous Opiate Agonists and Antagonists. Toronto: Pergamon Press, 1978:371-4.
213. 213. Oliveras JL, Guilbaud G, Besson JM: A map of the serotonergic structures involved in stimulation producing analgesia in unrestrained and freely moving cats. Brain Res 1979;164:317-22.
214. 214. Weil-Fugazza J, Godefroy F, Coudert D, Besson JM: Morphine analgesia and newly synthesized 5-hydroxytryptamine in the dorsal and the ventral halves of the spinal cord of the rat. Brain Res 1981;214:440-4.
215. 215. Wang BR, Senba E, Tohyama M: Ultrastructural investigation of substance P, leucine-enkephalin and 5-hydroxytryptamine-like immunoreactive terminals in the area of cremaster motoneurons of the male rat. Neuroscience 1989;28:711-23.
216. 216. Yaksh TL, Tyce GM: Resting and K+-evoked release of serotonin and norepinephrine in vivo from the rat and cat spinal cord. Brain Res 1980;192:133-46.
217. 3 receptor binding sites are on capsaicin sensitive fibers in the rat spinal cord. Eur J Pharmacol 1989;164:315-22.
218. 3 receptor subtypes modulate responses to noxious colorectal distension in the rat. Brain Res 1991;538:64-75.
219. 219. Richardson BP: Serotonin and nociception. Ann NY Acad Sci 1990;600:511-20.
220. 3 antagonists inhibit sensory neuropeptide release from the spinal cord. Neuroreport 1990;1:104-6.
221. 221. Angel A: Central neuronal pathways and the process of anaesthesia. Br J Anaesth 1993;71:148-63.
222. 3 receptors in N1 E115 neuroblastoma cells. Br J Pharmacol 1996;117:1507-15.
223. 3 receptors: focus on alcohols and anesthetic agents. Trends Pharmacol Sci 1996;17:95-9.
224. 224. Borison HL: Area postrema: chemoreceptor circumventricular organ of the medula oblongata. Progr Neurobiol 1989;32:351-90.
225. 3-receptor antagonist with anti-emetic properties. Br J Clin Pharmacol 1989;27:147-57.
226. 226. Kucharczyk J, Steward DJ, Miller AD (eds): Nausea and Vomiting: Recent Research and Clinical Advances. Boca Raton, FL: CRC Press, 1991.
227. 227. Gerschenfeld HM, Paupardin-Tritsch D, Deterre P: Neuronal responses to serotonin: a second view. In: Jacobs BL, Gelperin A (eds): Serotonin Neurotransmission and Behavior. Cambridge: MIT Press, 1981:105-30.
228. 1D receptor family. EMB3O J 1992;41:346-51.
229. 7) activating cAMP formation. Proc Natl Acad Sci USA 1993; 90:8547-51.
230. 230. Monsma JFJ, Shen Y, Ward RP, Hamblin MW, Sibley DR: Cloning and expression of a novel serotonin receptor with highly affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993;43: 320-7.
231. 6) receptor-molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 1993;193:268-76.
232. 7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993;11: 449-58.